Published in Blood on March 11, 2008
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Myeloproliferative disorders. Blood (2008) 3.37
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med (2013) 2.26
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood (2010) 2.16
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood (2011) 1.48
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood (2014) 1.44
STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood (2009) 1.17
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 1.14
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood (2009) 1.09
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One (2013) 1.08
Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol (2009) 1.06
Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech (2011) 0.98
JAK2 inhibitors: what's the true therapeutic potential? Blood Rev (2010) 0.97
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res (2010) 0.95
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. Ther Adv Hematol (2011) 0.95
Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am (2012) 0.93
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol (2011) 0.92
Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ (2012) 0.91
MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis (2012) 0.89
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol (2014) 0.88
The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. J Biol Chem (2010) 0.88
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol (2012) 0.87
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica (2011) 0.86
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (2011) 0.86
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol (2011) 0.85
Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.85
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J (2013) 0.84
Differential biological activity of disease-associated JAK2 mutants. FEBS Lett (2011) 0.84
Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep (2013) 0.84
Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. Regen Med (2010) 0.83
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J (2014) 0.83
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J (2011) 0.83
When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms. Ther Adv Hematol (2011) 0.83
Generation of a new congenic mouse strain with enhanced chymase expression in mast cells. PLoS One (2013) 0.83
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A (2013) 0.82
The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT (2012) 0.82
Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling. PLoS One (2011) 0.82
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Am J Pathol (2012) 0.80
Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn (2009) 0.80
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus (2009) 0.78
Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. Leukemia (2015) 0.78
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2011) 0.78
JAK2 inhibitors: are they the solution? Clin Lymphoma Myeloma Leuk (2011) 0.77
Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. Blood (2012) 0.77
Splenectomy normalizes hematocrit in murine polycythemia vera. PLoS One (2009) 0.77
JAK2 V617F and the evolving paradigm of polycythemia vera. Korean J Hematol (2010) 0.76
Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig (2015) 0.76
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One (2014) 0.76
JAK2(V617F)-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia (2016) 0.76
Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood (2016) 0.76
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. Exp Hematol (2011) 0.75
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight (2017) 0.75
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. Bioorg Med Chem Lett (2011) 0.75
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget (2015) 0.75
Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry. PLoS One (2014) 0.75
Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene (2015) 0.75
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Curr Med Chem (2011) 0.75
Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol (2015) 0.75
Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation. Blood (2016) 0.75
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk (2016) 0.75
Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice. Haematologica (2012) 0.75
Mouse models of diseases of megakaryocyte and platelet homeostasis. Mamm Genome (2011) 0.75
Hmga2 promotes the development of myelofibrosis in Jak2V617F knock-in mice by enhancing TGF-β1 and Cxcl12 pathways. Blood (2017) 0.75
A novel molecular mechanism of cellular transformation via a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci (2017) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 6.05
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Repeat-induced gene silencing in mammals. Nat Genet (1998) 4.74
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res (2006) 1.97
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood (2005) 1.91
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia (2007) 1.81
Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood (1998) 1.70
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood (2006) 1.50
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur J Haematol (2007) 1.33
In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol (2007) 1.26
Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol (2005) 0.99
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol (2007) 0.94
Classifying chronic myelomonocytic leukemia. J Clin Oncol (2001) 0.82
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell (2013) 3.31
NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature (2013) 2.63
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med (2013) 2.26
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc Natl Acad Sci U S A (2009) 1.58
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget (2014) 1.51
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood (2006) 1.50
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 1.48
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood (2006) 1.42
PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A (2004) 1.42
RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am J Hum Genet (2012) 1.34
MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. J Biol Chem (2006) 1.33
Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem (2002) 1.30
Ternary oxovanadium(IV) complexes of ONO-donor Schiff base and polypyridyl derivatives as protein tyrosine phosphatase inhibitors: synthesis, characterization, and biological activities. J Biol Inorg Chem (2009) 1.28
O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics (2014) 1.28
Exploration of α-aminophosphonate N-derivatives as novel, potent and selective inhibitors of protein tyrosine phosphatases. Eur J Med Chem (2012) 1.26
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood (2003) 1.24
Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. Nat Commun (2011) 1.23
Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun (2012) 1.21
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Mononuclear copper(II) complexes with 3,5-substituted-4-salicylidene-amino-3,5-dimethyl-1,2,4-triazole: synthesis, structure and potent inhibition of protein tyrosine phosphatases. Dalton Trans (2011) 1.17
AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem (2009) 1.17
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood (2013) 1.12
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis (2007) 1.12
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol (2006) 1.12
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol (2010) 1.12
Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am J Physiol Endocrinol Metab (2012) 1.12
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Synthesis, characterization, solid-state photo-luminescence and anti-tumor activity of zinc(II) 4'-phenyl-terpyridine compounds. J Inorg Biochem (2010) 1.09
Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. J Biol Chem (2013) 1.08
Human exposure to methylmercury through rice intake in mercury mining areas, Guizhou province, China. Environ Sci Technol (2008) 1.08
Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem (2009) 1.06
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res (2007) 1.04
The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res (2010) 1.03
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol (2008) 1.02
Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. J Biol Chem (2012) 1.01
Methylmercury accumulation in rice (Oryza sativa L.) grown at abandoned mercury mines in Guizhou, China. J Agric Food Chem (2008) 1.01
Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol (2012) 1.01
Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One (2012) 1.00
Synthesis and evaluation of oxovanadium(IV) complexes of Schiff-base condensates from 5-substituted-2-hydroxybenzaldehyde and 2-substituted-benzenamine as selective inhibitors of protein tyrosine phosphatase 1B. Dalton Trans (2012) 0.98
Mitochondrial uncoupling inhibits p53 mitochondrial translocation in TPA-challenged skin epidermal JB6 cells. PLoS One (2010) 0.98
Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. J Cell Biochem (2011) 0.96
Synthesis, characterization, and protein tyrosine phosphatases inhibition activities of oxovanadium(IV) complexes with Schiff base and polypyridyl derivatives. J Inorg Biochem (2010) 0.96
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum (2012) 0.96
Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. Cancer Epidemiol Biomarkers Prev (2009) 0.96
Potentiation of Th17 cytokines in aging process contributes to the development of colitis. Cell Immunol (2010) 0.96
20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer (2012) 0.95
Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem (2006) 0.95
Design, synthesis, bioactivity, and structure-activity relationship (SAR) studies of novel benzoylphenylureas containing oxime ether group. J Agric Food Chem (2008) 0.95
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol (2007) 0.94
Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med (2005) 0.94
SPAP2, an Ig family receptor containing both ITIMs and ITAMs. Biochem Biophys Res Commun (2002) 0.93
Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine. J Biol Chem (2003) 0.93
Environmental contamination of mercury from Hg-mining areas in Wuchuan, northeastern Guizhou, China. Environ Pollut (2005) 0.93
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res (2009) 0.92
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol (2011) 0.92
A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown origin. Int J Environ Res Public Health (2010) 0.91
c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One (2012) 0.90
PGC-1alpha attenuates neointimal formation via inhibition of vascular smooth muscle cell migration in the injured rat carotid artery. Am J Physiol Cell Physiol (2009) 0.89
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol (2014) 0.88
Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity. J Biol Chem (2012) 0.88
Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet (2013) 0.87
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol (2012) 0.87
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (2011) 0.86
Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. J Biol Chem (2010) 0.86
Novel anti-oxidative role of calreticulin in protecting A549 human type II alveolar epithelial cells against hypoxic injury. Am J Physiol Cell Physiol (2007) 0.86
Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol (2007) 0.86
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark (2007) 0.86
p-Aminoacetophenonic acids produced by a mangrove endophyte Streptomyces sp. (strain HK10552). Molecules (2010) 0.86
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol (2012) 0.85
Mercury distribution and speciation in water and fish from abandoned Hg mines in Wanshan, Guizhou province, China. Sci Total Environ (2009) 0.85
High sensitivity analysis of water-soluble, cyanine dye labeled proteins by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta (2009) 0.85
Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains. J Biol Chem (2003) 0.85
Integration of capillary isoelectric focusing with monolithic immobilized pH gradient, immobilized trypsin microreactor and capillary zone electrophoresis for on-line protein analysis. J Sep Sci (2010) 0.85
Identification of a variant form of tyrosine phosphatase LYP. BMC Mol Biol (2010) 0.85
Synthesis and biological activity of halophenols as potent antioxidant and cytoprotective agents. Bioorg Med Chem Lett (2010) 0.84
Design, synthesis, and insecticidal activities of new N-benzoyl-N'-phenyl-N'-sulfenylureas. J Agric Food Chem (2009) 0.84
Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am J Physiol Cell Physiol (2010) 0.84
Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol (2009) 0.84
Potent inhibition of protein tyrosine phosphatases by copper complexes with multi-benzimidazole derivatives. Biometals (2011) 0.84